Abstract-High pulse pressure, a measure of arterial aging, is an important predictor of cardiovascular and general mortality. It has been suggested that the genetic etiology of pulse pressure is the same as systolic blood pressure. We performed a genome-wide, multipoint, parametric linkage analysis in 26 large, extended Utah pedigrees to locate genes affecting pulse pressure. Four parametric models were considered, including dominant and recessive modes of inheritance involving genes for high and low pulse pressure. Linkage analysis revealed 11 regions with a logarithm of the odds (LOD) Ͼ1.5, including 2 regions attaining genome-wide suggestive evidence for linkage after accounting for multiple tests. Inspecting pedigree-specific multipoint linkage evidence suggested that these 2 regions localized to 15.7 cM on chromosome 8p (LODϭ2.89), between markers D8S136 and D8S1477, and 20.0 cM on chromosome 12q (LODϭ2.59), between D12S1300 and D12S2070. Both regions were identified better by pulse pressure compared with equivalent analyses with systolic or diastolic blood pressure. Results for pulse pressure overlapped favorably with those of others for related blood pressure phenotypes and support the hypothesis that genes with pleiotropic effects on blood pressure phenotypes do exist, but that the genetic etiologies are not identical. In conclusion, our results suggest that pulse pressure might be of use for identifying genes involved in blood pressure phenotypes and arterial aging. 
T here is mounting evidence that high pulse pressure (PP, calculated as the difference between systolic and diastolic blood pressures) is an independent and important component of risk to cardiovascular disease and mortality and might be a superior predictor to systolic blood pressure (SBP). In men Ͼ60 years, both SBP and PP were found to be predictors of cardiovascular disease, 1 and high PP was found to be an independent risk factor for total and cardiovascular mortality in several studies. [2] [3] [4] [5] [6] PP has been suggested to be superior to SBP as a predictor of carotid stenosis 7 and coronary heart disease 8 and was found to be superior to SBP, and independent of diastolic blood pressure (DBP), for predicting coronary heart failure. 9 The superiority of PP was also suggested for predicting cardiovascular and total mortality. 6 DBP first increases with age and then levels off or decreases after age 50 years, whereas SBP increases throughout life. 10 -13 PP therefore increases with age and is correlated with SBP. The age-dependent increase in PP (and SBP) is largely determined by the progressive stiffening of the central elastic arteries and reflects the biologic aging of the arterial system. 12,14 -16 PP is therefore regarded as an index of arterial aging. In the spontaneously hypertensive rat, PP has also been shown to be associated with arterial stiffness. 17 This leads to the hypothesis that hypertension is due to acceleration of arterial aging 18 and is a disorder of aging. 19 Little is currently known of the genetic basis for PP variation in the population. There is empirical evidence to suggest that the genetic etiologies of the steady-state and pulsatile components of blood pressure are different. Genome-wide linkage analyses for both SBP and DBP do not systematically produce coincident loci of interest, although some do overlap. 20 -25 In the Lyon hypertensive rat, different loci are involved in the steady and pulsatile components. 26 SBP and PP are both measures of the pulsatile component of blood pressure. Of interest is whether PP is a superior trait for identifying genetic loci for pulsatile blood pressure and whether the same genetics underlies SBP and PP. Thus far, only a single genome-wide linkage analysis has been performed for PP, 27 which suggested a common genetic etiology for SBP and PP. This study aims to further investigate the genetic determinants for the various components of blood pressure.
Methods

Study Subjects
Ninety-eight pedigrees were ascertained for early coronary heart disease deaths, early strokes, and early-onset hypertension. Most pedigrees were ascertained as relatives (4 to 7 generations) of sibships with at least 2 coronary heart disease deaths Ͻ55 years or stroke deaths Ͻ75 years. The initial sibships were identified from a state-wide registry of 140 000 death records computer-linked to genealogic records for 1.2 million Utahns. 28 The remaining pedigrees were ascertained from probands from the Utah Center for Hypertension Detection and Follow-up Program. Clinical, biochemical, medication, and questionnaire variables have been previously described. 29 Sitting blood pressures were measured by an automated machine that traced the blood pressure waveform onto a disk for subsequent reading (Infrasonde SR-2, Sphygmetrics, Inc); the mean of 4 measurements was used for analysis. PP was calculated as the difference between SBP and DBP and was available for 2444 individuals (Table 1) . Genotyping for 1916 subjects was provided by the Mammalian Genotyping Service (set 10). Incompatibilities and genotyping errors were identified by PAP 30 and PEDCHECK, 31 resolved, or deleted. Markers were analyzed by using Marshfield map positions (http://research.marshfieldclinic.org/genetics). Maximum-likelihood marker-allele frequencies were calculated from the data.
Twenty-six large, extended pedigrees were chosen from the 98 to maximize the statistical power to detect linkage under heterogeneity. The pedigrees selected were those with expected logarithm of the odds (ELOD) scores 32,33 Ն0.5 for 1 of the 4 genetic analysis models (see Statistical Methods). These more powerful pedigrees allow for a more informative analysis under heterogeneity, because each has the potential to show both positive and negative linkage evidence. The uninformative pedigrees add "noise" with little additional power and hence, were not considered for analysis. The pedigrees analyzed ranged in size from 16 to 175 members, for whom both phenotypic and genotypic data were available for between 13 and 100 individuals (1454 total subjects). All pedigree members who participated in the study gave informed consent. The study design and protocols were approved by appropriate institutional review boards at the University of Utah.
Statistical Analyses
Phenotype PP for unmedicated subjects was adjusted in a multiple regression model for sex, age, age 2 , and body mass index before linkage analysis. It has been suggested that antihypertensive drugs have direct arterial wall effects. 34 For the 125 subjects taking antihypertensive medications, a PP value of 55 mm Hg was assigned for analysis, unless their observed medicated value was higher, in which case that value was used. This approach assumes that medicated individuals had a minimum PP of 55 mm Hg at the time of treatment onset. This fixed value compares well with that from other studies 35, 9 (53 and 62 mm Hg, respectively). In our population, 55 mm Hg corresponds to 1 SD above the population mean for unmedicated individuals after correction for sex, age, age 2 , and body mass index (Table 1) . One hundred individuals were assigned a value of 55 mm Hg, and 25 retained their observed values. A substitution approach for managing medicated subjects has many advantages. These individuals contribute important information to the familial component of PP variance and should lead to increased power. 36, 37 There is no overcorrection and loss of power, which might occur when using methods such as regression to correct for medication. It remains conservative, because fixing a large number of individuals at the same value leads to a decrease in the overall phenotypic variability.
Linkage Analysis
Multipoint, quantitative, parametric analyses were performed by MCLINK, a Markov chain Monte Carlo method that uses blocked Gibbs sampling 38 to estimate the multipoint inheritance vectors and that can be performed on large, extended pedigrees without any reduction in pedigree structure. 39 For each of 4 genetic models, the TLOD ("theta" LOD) linkage statistic was calculated. 40, 41 The TLOD is a robust, multipoint linkage statistic that is a combination of multipoint and 2-point linkage paradigms. Multipoint inheritance vectors are estimated from all available marker data and are used to determine the inheritance probabilities for specific markers. A 2-point paradigm is then implemented to calculate the linkage statistic, maximized over the recombination fraction (), hence "theta" LOD. Classic multipoint linkage analysis does not maximize over , rather ϭ0, and is not robust to errors in the specified genetic model. 42 HOMOG 32 was used to calculate heterogeneity TLODs.
Genetic Models
Commingling analysis was performed to estimate genetic parameters for the parametric model. There was significant evidence that 2 normal distributions with means of 44.77 mm Hg and 59.53 mm Hg (SDϭ8.81 mm Hg) fit the phenotypic data better than did a single normal distribution (PϽ1.0ϫ10 Ϫ10 ). The penetrance functions were constructed on the basis of the ratio of the normal density functions, as is standard in quantitative parametric modeling. Models for high and low PP were developed, such that the "disease" allele predisposed to high or low PP, respectively. Both dominant and recessive models were considered. Gene frequencies were selected to be 0.01 for dominant models and 0.10 for recessive models. 43 
Significance Thresholds
Genome-wide thresholds to account for multiple testing of markers and models were calculated. 44 This method extends that previously proposed for an infinitely dense marker map for a single model. 45 For our data, these thresholds were 2.5 (Pϭ3.5ϫ10 Ϫ4 ) for suggestive genome-wide evidence (1 false-positive across all genome-wide analyses) and 3.8 (Pϭ1.4ϫ10 Ϫ5 ) for significant evidence (0.05 false-positive). In addition to these 2 thresholds, we report all linkage findings Ͼ1.5 (Pϭ0.004) to allow for comparison with other studies.
Results
Heritability and Power
The heritability of PP was estimated to be 0.25 and was highly significant (PϽ1.0ϫ10 Ϫ7 ). In the same sample, heritabilities for SBP and DBP were lower, 0.19 and 0.21, respectively, but also highly significant. All estimates were calculated with SOLAR. 46 Pedigree ELODs ranged from 0.531 to 2.753. Power varied by model and was highest for the low-dominant model and lowest for the high-recessive model. The high-recessive model indicated only reasonable evidence to detect linkage signals at the 1.5 level and is not discussed further. With the assumption of no heterogeneity, the 3 remaining models indicated good power (Ͼ80%) to detect suggestive evidence for linkage, and both low models had excellent power BMI indicates body mass index. *All individuals for whom PP data were available.
(Ͼ95%) for significant evidence. In addition, under heterogeneity of 50%, all 3 models had at least 50% power to detect linkage signals Ͼ1.5. The low models were superior and maintained good power (Ͼ75%) to detect genome-wide suggestive evidence for linkage. 
Linkage Results for PP
Localization of Genome-Wide Suggestive Regions
For localization, the regions on chromosomes 8p and 12q were investigated in a pedigree-specific manner by classic multipoint LOD analysis (ϭ0). Pedigrees with LOD Ͼ0.588 (nominal Pϭ0.05) were identified for each region, and multipoint LOD evidence was plotted against centimorgan position. A sum of LOD values for linked pedigrees (sum-LOD) was calculated to illustrate the combined localization evidence for linked pedigrees. In each pedigree, recombinant events, which define the shared region between individuals with similar quantitative scores, can be estimated by the position at which linkage evidence decreases. We considered a drop of Ͼ0.5 LOD unit to indicate a recombination event and conservatively considered the outer marker as the recombinant position. Region sizes were estimated both by pedigree recombinant boundary positions and by the 1-LOD drop from the peak of the sumLOD. Figures 1 and 2 illustrate the pedigree-specific support for the regions on chromosomes 8p and 12q, respectively. Table 3 shows additional characteristics for both regions.
For both regions, several linked pedigrees were identified, with no conflicting recombinants for region localization. The multipoint sumLODs were high for both regions (8p, 8.38; 12q, 5.16). Estimated region sizes were relatively large, as would be expected for a genome-wide map with an average resolution of 9.5 cM. However, the slow decrease in the pedigree LOD evidence across several markers indicated that markers were not informative in all haplotype carriers in these pedigrees, and the positions of recombinants could not be clearly pinpointed. This suggests that both regions could be narrowed by increasing marker density. With the current data, the minimum region size on chromosome 8p is 7.1 cM and on chromosome 12q is 10.3 cM, both estimated statistically from the 1-LOD drop from the sumLOD peak.
Overlap With Regions for SBP and DBP
For comparison, linkage analyses of SBP and DBP were performed. Table 4 includes results found in the current study for SBP or DBP (TLOD Ͼ1.0) in the PP regions (Table 3 ). Of note is that the chromosome 8p region was not identified for either SBP or DBP and that the region on chromosome 12q was substantially higher for PP (2.59 compared with 1.21 for DBP). Of the remaining 9 regions, PP scores were superior for 3 regions (ϩ0.48 to ϩ1.52), similar for 5 regions (Ϫ0.40 to ϩ0.41), and inferior for 1 region on chromosome 3p (Ϫ0.49). Table 5 shows 5 regions on chromosomes 3, 4, 6, 10, and 18 that were identified for SBP or DBP (TLOD Ͼ1.5) but not by PP.
Discussion
Our findings, similar to those of Atwood and colleagues, 27 illustrate considerable concordance between regions identified for PP and for SBP and DBP. However, in contrast, we found that some regions were clearly identified better by PP, with 3 regions that were not identified at all with SBP or DBP (8p, 8q, and 16p). Of course, we do not know which if any of the regions are true or false-positives, so issues of power cannot be assessed by our study. However, it does suggest that these traits do not always segregate in precisely the same way and that 1 trait cannot simply be used as a proxy for another. In particular, we have identified 2 genome-wide suggestive regions for PP, localized to a 7.1 cM region and a 10.3 cM region on chromosomes 8p and 12q, respectively, that would have been overlooked had only the more standard SBP or DBP analysis been performed. The superior linkage evidence for PP in the current study might suggest that these regions contain genes more closely tied to variation in vessel stiffness.
Comparison With Published Results
We know of only 1 other genome-wide linkage analysis of PP. 27 For meaningful comparison, all marker positions have been converted to those specified on the current Marshfield genetic map. Regions identified with linkage evidence Ͼ1.5 by this prior study 27 were on chromosome 7 (2.04; D7S1799 at Marshfield position 113.92 cM), chromosome 8 (1.98; D8S1100 at 154.02 cM), chromosome 18 (1.95; D18S844 at 116.44 cM), chromosome 20 (1.58; D20S477 at 45.89 cM), Table 4 shows the 15 regions identified for PP (LOD Ͼ1.5) in either the current study or that of Atwood and colleagues. 27 Overlapping signals between these 2 PP studies are illustrated, in addition to published findings in these locations for other blood pressure traits.
Only modest overlap was observed between the current study and that of Atwood and colleagues 27 when they were compared for signals for PP alone. One region on chromosome 8q contained linkage evidence Ͼ1.5 in both the current and the Atwood 27 study (1.53 and 1.98, respectively). This region on chromosome 8q appears distinct from the one strongly suggested by the current study on 8p, because the linkage evidence in both studies decreases appreciably in between and neither region appears to be merely residual linkage evidence from the other. However, the 2-point LOD scores used by Atwood and colleagues 27 are not ideal for localization.
Comparison of the 15 PP regions (11 from the current study, 5 from Atwood et al, 27 1 overlapping) with those published for other blood pressure traits 20 -24,36,47-51 are also shown in Table 4 . Published linkage signals for SBP, DBP, hypertension, mean arterial pressure, postural change in SBP, and orthostatic hypotensive disorder were found to overlap with regions identified for PP. It is interesting to note that for 7 of the total 15 regions, the linkage signal was higher for PP (either in the current or the Atwood study 27 ) by ϩ0.17 to ϩ1.38 LOD units compared with all other studies of blood pressure traits. However, there are difficulties in directly comparing LODs that use different linkage methods across studies, 52 and this should be borne in mind.
Perspectives
Our results support the hypothesis that there are genes with pleiotropic effects on multiple blood pressure traits. However, the genetic etiologies of these traits might not be identical, and unique gene pathways might exist for the different components of blood pressure, both between and within the pulsatile and steady components. The results here suggest that PP might be useful for identifying regions and genes involved in both arterial aging and blood pressure phenotypes. 
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